logo
Plus   Neg
Share
Email

Roche Reports FDA Approval Of Rozlytrek - Quick Facts

Roche (RHHBY) announced the US FDA approval of Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, the FDA has granted accelerated approval to Rozlytrek for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation.

Sandra Horning, Roche's Head of Global Product Development, said: "Rozlytrek is the first FDA-approved treatment that selectively targets both ROS1 and NTRK fusions, and, importantly, has also shown responses in these rare cancer types that have spread to the brain."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Xerox Holdings Corp. (XRX) dropped its $24 per share hostile bid to acquire HP Inc. (HPQ), citing the current global health crisis and economic uncertainty caused by the COVID-19 pandemic. American Airlines Group has extended its offer to waive change fees for customers who purchase travel tickets through April 30, in response to lower travel demand due to the coronavirus or COVID-19 pandemic. The offer is available for any of American Airlines' published non-refundable fares. The airline had earlier waived change fees for customers who purchased tickets through April 15. The U.S. Consumer Product Safety Commission or CPSC is advancing with its proposed rule to ban padded, pillow-like crib bumpers amid increasing incidents of infant injury and deaths. In a statement, the agency said it voted unanimously last week to move forward with rulemaking on a federal safety standard for crib bumpers.
Follow RTT
>